Winton Group’s Outlook Therapeutics OTLK Stock Holding History

Winton Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-811	Closed	-$12K	–	1463
2020 Q3	$12K	Buy	+811	New	+$18.1K	﹤0.01%	1450

Other funds holding OTLK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Winton Group's OTLK Position: Q4 2020 in Review

Winton Group sold out of Outlook Therapeutics (OTLK) in Q4 2020, closing a stake of 811 shares — an estimated $12K sold.

Winton Group first reported a position in OTLK in Q3 2020 and held it in 1 quarter. The position peaked at $12K in Q3 2020. 30 funds tracked by Wall St. Rank hold OTLK as of Q4 2020.

Winton Group reported no remaining Outlook Therapeutics position as of Q4 2020 after selling out during the quarter.
Winton Group sold 811 Outlook Therapeutics shares in Q4 2020, an estimated $12K.
Winton Group first reported a position in Outlook Therapeutics in Q3 2020 and held it in 1 quarter.
Winton Group's Outlook Therapeutics position peaked at $12K in Q3 2020.
30 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.